
Herantis H2 2022 - Important progress

Redeye returns with a research update following Herantis H2 report. We slightly raise our base case and expect Herantis to take the important step back into the clinic now in H1 2023.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Herantis H2 2022 - Important progress